Access Scientific Inc., makers of the Picc Wand and Power Wand IV catheters, closed a $10 million equity financing round.
Investment was led by CAC, a private equity firm, and followed by Access Scientific’s previous investors.
The company’s IV catheters are designed reduce patient discomfort by allowing blood tests to be drawn and fluids and medications to be delivered through a single device, which can last the duration of an entire hospital stay.
"The commitment from CAC and our existing investors will allow us to improve the hospital in-patient experience worldwide with this groundbreaking new vascular access technology," said Dr. Steve Bierman, CEO of Access Scientific in a release.
Here’s a roundup of other dealflow and investment news:
- Teleflex announces prices for $250 million offering
Teleflex Inc. (NYSE:TFX) released pricing for the $250 million preferred stock offering that it announced last week, and moved the maturity date forward. The Senior Subordinated notes will be offered at 100 percent of their principal amount and will mature on June 1, 2019. The notes will pay on June 1 and December 1 of each year at a 6.875 interest rate. The Limerick, Pa.-based medical device maker expects to rake in $245.8 million, according to the SEC filing.
- EndoSphere closes an oversubscribed and undisclosed pivotal financing round
Endosphere Inc., maker of an implantable and incisionless weight loss device, announced an oversubscribed Series A preferred financing round. The value of the financing was not disclosed. The company plans to use the funds to expand its intellectual property assets and complete additional clinical product testing.
- Health video company raises $1.7 million
SBR Health Inc. closed a $1.7 million equity and Series Seed preferred stock financing round. The Cambridge, Mass.-based company develops real-time video communication software for the health industry.
- SeptRx raises $2.7 million to fund CE Mark trial
SeptRx Inc. landed $2.7 million in Series A financing led by Nitinol Devices & Component Inc. The Fremont, Calif.-based company plans to use the funds to carry it through CE Mark registration of its SeptRx platform for percutaneous transcatheter closure of a heart defect known as PFO, which is linked to 20 percent of all strokes, according to the release.
- Crux lands a $12 million investment round
Crux Biomedical Inc., developer of an implantable vena cava filter, announced a $12 million investment round led by Three ARch Partners, and followed by current investors Alloy Ventures and Emergent Medical Partners.
- Shine Medical picks up $11 million
SHINE Medical Technologies secured $11 million in venture capital funding as part of its bid to develop a medical isotope manufacturing plant.
- Quintiles completes refinancing
Quintiles Transnational Corp. announced that it completed arrangements for its $2.2 billion credit facility, with a $225 million first lien revolving credit facility due in 2016 and a $2 billion first lien term loan B due in 2018.
- Obama Administration’s Investing Innovations Initiative hands out $5 million to spur health IT
The White House launched a new initiative designed to spur innovation in health information technology this week, and awarded the first $5 million to two projects, Capital Consulting Corp. and Health 2.0 LLC. The Investing Innovations Initiative was made possible by the America Competes Reauthorization Act of 2010.
- Revolutions Medical posts preliminary prospectus for 10 million shares of high risk stock
Revolutions Medical Corp. (PINK:RMCP) posted a preliminary prospectus with the federal SEC for the resale of up to 10 million shares of common stock valued at .001 cent per share. The filing noted that the investment involves a high degree of risk, and investors should only purchase the stock if they can afford a complete loss.